Role of CRISPR/Cas9 in Genetic Manipulation of ROS1 and EGFR Genes using Synthego Platform

Mutations and fusions in kinase enzymes are often observed in cancer prognosis. The growth and survival of tumor cells depend on the activation of kinase enzymes which when activated unrestrained can lead to the uncontrolled division of malignant lung cells. Thus, their inhibition is viewed as a promising and effective anti-cancer therapy. ROS1 and EGFR are two tyrosine kinases that have been explored as the genes responsible for Non-Small Cell Lung Cancer (NSCLC). By interrupting the unchecked division of these genes, the development of malignant lung cancer cells can be blocked. The results show 4 of the top-line RNAs for altering the gene quality as well as the target sequences relevant to cleavage by that gRNA, 4 for each gene. We propose a genetic approach of controlling the ROS1 and EGFR genes guided by CRISPR/Cas-9 to guarantee fewer symptoms and an increasingly powerful treatment, by the use of computational tools.